State-of-the-Art Clinical Symposium On Demand 2026
During the State-of-the-Art Clinical Symposium (SOTA), key opinion leaders presented a range of content in areas such as therapeutic developments, recent research findings, and scientific advances.
$67500
SOTA-OD-26
ACR Non-Member: $675
ACR Member: $450.00
ARP Member: $225.00
ARP Non-Member: $450.00
Student/Resident/Transitional Member: $225.00
Self-Paced
Lupus, Other Rheumatic & Connective Tissue Disorders, Pediatric, Rheumatoid Arthritis
Monday, May 4, 2026, 12:00 AM
Thursday, May 3, 2029, 11:55 PM
CME, ABIM MOC, Participation
Fellows in Training, Nurses, Pharmacists, Physician Assistants, Rheumatologists, Rheumatology Interprofessionals, Program Directors
9.00
9.00
9.00
Tags:

Description

During the State-of-the-Art Clinical Symposium (SOTA), key opinion leaders presented a range of content in areas such as therapeutic developments, recent research findings, and scientific advances.


Topics

  • Under Pressure: Screening, Diagnosis, and Treatment of Pulmonary Hypertension for the Rheumatologist 
    Stephen Mathai, MD, MHS 

  • Interstitial Insights 
    Bradford Bemiss, MD 

  • Combined Q&A 
    Stephen Mathai, MD, MHS; Bradford Bemiss, MD 

  • Stuck in Transit: GI Manifestations in Scleroderma 
    Zsuzsanna McMahan, MD, MHS 

  • Vessels in Distress: Recommendations on If and How to Taper Treatment 
    Alexandra Villa-Forte, MD, MPH, FACP 

  • Vectors on the Move 
    Cassandra Calabrese, DO 

  • Little Joints, Big Clues: A Look into Pediatric Rheumatology 
    Sangeeta Sule, MD, PhD 

  • Precision in Psoriatic Arthritis: Updates on Diagnosis and Treatment 
    Ana-Maria Orbai, MD, MHS 

  • Axial Spondyloarthritis 
    Liron Caplan, MD, PhD 

  • SLE in the Real World: Complexities and Challenges 
    Saira Sheikh, MD 

  • Lupus Nephritis Reloaded: New Drugs, New Tools, New Hope 
    Ali Duarte-Garcia, MD 

  • Combined Q&A 
    Saira Sheikh, MD; Ali Duarte-Garcia, MD 

  • Joint Action: Advances in Rheumatoid Arthritis 
    Diane Horowitz, MD, RhMSUS 

  • Breaking the Resistance: Tackling Myositis 
    Didem Saygin, MD 

  • CPPD: Classification Criteria, Outcomes, and Treatment in an Underdiagnosed Disease 
    Ann Rosenthal, MD, MACR 

  • Granuloma Games: Real World Challenges in Sarcoidosis 
    Arthur Yee, MD, PhD 

  • Breaking the Clot: Updates in Antiphospholipid Antibodies and Thrombotic Microangiopathies 
    Jason Knight, MD, PhD 


Target Audience

Rheumatologists, nurses, pharmacists, physician assistants, program directors, and fellows in training.

Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP.


Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Review the most up-to-date evidence-based treatment approaches in the diagnosis and management of rheumatic diseases including psoriatic arthritis, rheumatoid arthritis, and osteoarthritis
  • Review more complex clinical presentations, disease pathology, and treatment modalities in patients with lupus, refractory or recurrent idiopathic inflammatory myopathy, sarcoidosis, scleroderma
  • Summarize updated guidelines for complex manifestations of rheumatic disease, specifically pulmonary hypertension and interstitial lung disease, and implement current recommendations for screening and treatment
  • Review most up-to-date guidelines and clinical recommendations in pediatric rheumatology diseases
  • Recognize Lyme disease and other tick-borne illnesses that present phenotypically similar to rheumatic disease and review best treatment modalities for these patients


CE & MOC Information

In support of improving patient care, the American College of Rheumatology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Provider Number: 0003797

See the ACR's CE Mission Statement. For more information, download the AMA PRA Booklet. 

Credit must be claimed by May 3, 2029, at 11:59 PM ET.  

All participating healthcare professionals should claim only the credit commensurate with the extent of their participation in this activity. 


Available Credit

  • CME: 9.00 AMA PRA Category 1 Credit(s)™
  • ABIM MOC: 9.00 Medical Knowledge Points
  • ANCC: 9.00 Contact Hours


AMA Designation Statement

The American College of Rheumatology designates this enduring material for a maximum of 9.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Recognition Statement: American Board of Internal Medicine (ABIM)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board. 

After submitting a reflective statement with key takeaways from the activity, MOC points will be applied for ABIM diplomates to the ABIM diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal.


Financial Relationship Disclosures

ACR Disclosure Statement

It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.


Nature of Financial Relationships

All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:

  1. Advisor or review panel member
  2. Consultant
  3. Employee
  4. Officer or Board Member
  5. Grant/research support
  6. Speaker/honoraria includes speaker’s bureau, symposia, and expert witness
  7. Independent contractor
  8. Executive role and/or ownership interest
  9. Royalties and/or patent beneficiary
  10. Intellectual property/patents
  11. Stock options or bond holdings in a for-profit corporation or self-directed pension plan
  12. Private investigator
  13. Expert witness
  14. Equity interest
  15. Other: specify details

None: Has no relevant financial relationship(s) with ineligible companies to disclose.

All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. State-of-the-Art Symposium Faculty Disclosure Mitigation


Acknowledgement of Commercial Support

No commercial support was provided for this activity.


Educational Activity Policies

See ACR educational activity policies, including the online enduring activity refund policy.